Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

M. Sticherling*, U. Mrowietz, M. Augustin, D. Thaçi, N. Melzer, C. Hentschke, J. Kneidl, C. Sieder, K. Reich

*Corresponding author for this work
23 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology